Q-omics provides the consensus-scored TMEM234 profile across patient tissues and cancer cell-line models. TMEM234 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM234 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, TMEM234 RNA expression shows 18,485 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where TMEM234 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM234 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM234 survival associations across molecular data types. TMEM234 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM234 RNA expression–survival associations across cancer types. High TMEM234 expression shows unfavorable associations in KIRC, LIHC, LGG and KICH, but favorable associations in CHOL and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM234 RNA expression.
This table summarizes TMEM234 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM234. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM234 shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, HNSC and STAD. The KIRC box plot shows higher TMEM234 RNA expression in tumor versus normal tissue (log2 FC = +0.805, t-test p < 0.001).
This table shows molecular features associated with TMEM234 in patient tissues and cancer cell lines. In patient samples, TMEM234 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM234 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
